Roche Q1 sales up 10%, confirms 2022 outlook
Swiss drugmaker Roche's first quarter sales rose 10%, driven by drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia, and on strong U.S. demand for rapid COVID-19 antigen tests.